April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Application of Active-type Vitamin D3 for External Use to Treat Meibomian Gland Dysfunction of Mice
Author Affiliations & Notes
  • Kai Jin
    Ophthalmology, Keio University, Tokyo, Japan
  • Motoko Kawashima
    Ophthalmology, Keio University, Tokyo, Japan
  • Masataka Ito
    Developmental Anatomy, National Defense Medical College, Tokyo, Japan
  • Akiko Ito
    Ophthalmology, Keio University, Tokyo, Japan
  • Samuel Connell
    Ophthalmology, Keio University, Tokyo, Japan
    Medical and Veterinary Sciences, University of Bristol, Bristol, United Kingdom
  • Kokoro Sano
    Ophthalmology, Keio University, Tokyo, Japan
  • Kazuo Tsubota
    Ophthalmology, Keio University, Tokyo, Japan
  • Footnotes
    Commercial Relationships Kai Jin, None; Motoko Kawashima, NRL pharma (F); Masataka Ito, None; Akiko Ito, None; Samuel Connell, None; Kokoro Sano, None; Kazuo Tsubota, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 15. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kai Jin, Motoko Kawashima, Masataka Ito, Akiko Ito, Samuel Connell, Kokoro Sano, Kazuo Tsubota; Application of Active-type Vitamin D3 for External Use to Treat Meibomian Gland Dysfunction of Mice. Invest. Ophthalmol. Vis. Sci. 2014;55(13):15.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To investigate the efficacy and safety of active-type vitamin D treatment of meibomian gland dysfunction (MGD) in mice.

Methods: Methods: Meibomian gland orifices of the upper eye lid were cauterized and made creating a meibomian gland dysfunction model was created using male C57BL/6JJc1 mice (N=120). MGD mice were randomly divided into three groups: : maxacalcitol (22-oxacalcitriol, an analog of active vitamin D), vaseline (petroleum jelly) control and blank control. Maxacalcitol or vaseline were applied on the upper lid margin a day daily for 2 months. Maxacalcitol or vaseline were also applied on the normal lid margin to evaluate thetheir safety. The cChanges of in the tarsus surface, conjunctiva, cornea and eyelid margin morphology were observed by microscope, and pathological alteration of meibomian gland were investigated on day 2, day 5, day 7, 1 week, 2 weeks , 1 month and 2 months.

Results: The atrophy of the meibomian glands can be alleviated by maxacalcitol application compared to vaseline and blank control. The cornea is was not affected by maxacalcitol application up to during our 2 month observation.

Conclusions: Maxacalcitol, active-type vitamin D3 possesses the ability to attenuate MGD and is a potential safe treatment of MGD.

Keywords: 486 cornea: tears/tear film/dry eye • 637 pathology: experimental • 475 conjunctivitis  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×